Skip to content

Psilocybin for anxiety: all studies

Page 14 of 31: studies 131 to 140 of 305, newest first. Back to the psilocybin for anxiety overview

Research

Exploring the relationship between mental health, drug use, personality, and attitudes towards psilocybin-assisted therapy

Journal of Psychedelic Studies August 21, 2023 Benjamin M. Ross, James T. Neill 6 citations

Abstract Background Psilocybin, the psychoactive compound in magic mushrooms, is increasingly discussed in terms of its psychotherapeutic potential; however, little is known about community attitudes towards psilocybin assisted therapy (PAT). Aims To address the question: What are the public's attitudes towards psilocybin and psilocybin-assisted therapy? And what factors explain these...

Psilocybin's Emerging Role in Combating Depressive Disorder

Journal of Education Health and Sport August 8, 2023 Anna Jaremek, Joanna Kępa, Norbert Kandefer et al.

In this review paper, we delve into the potential applicability of psilocybin - a naturally synthesized psychedelic substance found within select species of fungi, as a prospective avenue for depression treatment. Depression, a widespread psychological malady affecting countless individuals across the globe, often proves stubborn against existing treatment modalities, necessitating exploration...

Personality Change in a Trial of Psilocybin Therapy vs Escitalopram Treatment for Depression – CORRIGENDUM

Psychological Medicine July 19, 2023 Brandon Weiss, Induni Ginige, Lu Shannon et al. 1 citation

An abstract is not available for this content. As you have access to this content, full HTML content is provided on this page. A PDF of this content is also available in through the 'Save PDF' action button.

Psilocybin-assisted psychotherapy for cancer-related anxiety and depression

International Journal of Gynecological Cancer July 18, 2023 Dan Yaniv, L. Ramondetta, L. Cohen et al.

Women with gynecologic cancers face various physical and psychological challenges throughout their treatment journey. Late stages associated with poor prognosis, along with chronic side effects of treatment, often leave women with existential uncertainty stemming from unpredictable disease trajectory and continuous fear of death. Recently, a patient in her late 30s (JN) with endstage ovarian...

Outcomes of usage of psychedelics by people reporting an eating disorder in clinical and non-clinical settings: a scoping review

Advances in Mental Health July 13, 2023 Jorge Valdiviezo‐oña, Lizbeth Toscano-Molina, Juan Fernando Chávez et al. 4 citations

Objective To map the studies reporting the use of psychedelics in clinical and non-clinical settings by people reporting an eating disorder (ED) and their outcomes.Method To be included, peer-reviewed articles had to be written in English or Spanish and had to address the usage of psychedelics by people reporting an ED. Searches were conducted on PubMed, Scopus, and Web of Science. Data on key...

Ethopharmacological evaluation of antidepressant-like effect of serotonergic psychedelics in C57BL/6J male mice

Research Square (Research Square) July 7, 2023 Rika Takaba, Daisuke Ibi, Keisuke Yoshida et al. 4 citations preprint

Abstract Serotonergic psychedelics such as psilocybin, lysergic acid diethylamide, and DOI exert a hallucinatory effect through serotonin 5-HT 2A receptor (5-HT2A) activation. Recent studies have revealed that serotonergic psychedelics have therapeutic potential for neuropsychiatric disorders, including major depressive and anxiety-related disorders. However, the involvement of 5-HT2A in...

Psychoactive substances in psychotherapy - A vision for the future? – A systematic review on Psilocybin

July 6, 2023 Jenny Tetem, Tamara Fischmann, Tim Julian Möller preprint

This work is a literature review on the use of psilocybin in psychotherapeutic treatment of mental illnesses. The review answers the question of what opportunities and risks are associated with the use of the psychoactive substance psilocybin. Peer-reviewed studies between 2017 and 2022 were included. Nine studies were found regarding the following indications: tobacco addiction, anxiety and...

Addressing the Current Knowledge and Gaps in Research SurroundingLysergic Acid Diethylamide (LSD), Psilocybin, and Psilocin in RodentModels

Current Topics in Medicinal Chemistry July 6, 2023 Udoka C. Ezeaka, Hye Ji J. Kim, Robert B. Laprairie 1 citation

Abstract: Lysergic acid Diethylamide (LSD), psilocybin, and psilocin are being intensively evaluated as potential therapeutics to treat depression, anxiety, substance use disorder, and a host of other psychiatric illnesses. Pre-clinical investigation of these compounds in rodent models forms a key component of their drug development process. In this review, we will summarize the evidence...

Self-treatment of parental neglect-induced mixed anxiety and depressive disorder with psilocybin – A retrospective case study

June 9, 2023 Mika Turkia 3 citations preprint

This article presents the case of a young woman in her mid-twenties with a history of depression since childhood. She lived with a mother who failed to take care of her. The patient cared for the emotional needs of the mother instead of the mother caring for the daughter's needs. Her father was mostly absent. Already around the age of thirteen, the patient was severely depressed and was...

The treatment of abandonment anxiety with MDMA and LSD

June 9, 2023 Mika Turkia 2 citations preprint

This retrospective study presents the case of a young woman in her mid-twenties who suffered from insecurity and abandonment-related anxiety, which intensified after a breakup of her relationship. Her parents' alcoholism and schizophrenia, as well as emotional and physical violence, had been a part of her childhood, but they had appeared 'normal' to her. Her parents and relatives had not...